Results 131 to 140 of about 42,483 (237)

Evaluation of a Novel Electric Health Record Sidecar Application to Display Rheumatoid Arthritis Clinical Outcomes During Clinic Visits: Results of a Stepped‐Wedge Cluster Randomized Pragmatic Trial

open access: yesArthritis Care &Research, Volume 78, Issue 8, Page 1006-1015, August 2026.
Objective We developed a novel electronic health record sidecar application to visualize key rheumatoid arthritis (RA) outcomes, including disease activity, physical function, and pain, via a patient‐facing graphical interface designed for use during outpatient visits (“RA PRO dashboard”).
Gabriela Schmajuk   +16 more
wiley   +1 more source

Effect of photobiomodulation on pain and quality of life in fibromyalgia syndrome: a systematic review. [PDF]

open access: yesLasers Med Sci
G A S   +6 more
europepmc   +1 more source

Dual Targeted Therapy as a Treatment Strategy for Refractory Psoriatic Arthritis: Real‐World Effectiveness and Safety From a Prospective Cohort

open access: yesACR Open Rheumatology, Volume 8, Issue 8, August 2026.
Objective To describe patient profiles, treatment patterns, clinical outcomes, and safety of intentional dual biologic or targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD) therapy in psoriatic arthritis (PsA). A subset of patients with PsA continue to experience persistent inflammation despite b/tsDMARD monotherapy.
André Lucas Ribeiro   +11 more
wiley   +1 more source

Pain Sensitivity Profiles Are Associated With Muscle Biomechanics and Clinical Pain in Persons With Symptomatic Knee Osteoarthritis

open access: yesACR Open Rheumatology, Volume 8, Issue 8, August 2026.
Objective There is growing evidence that knee osteoarthritis (OA), a significant source of chronic pain, is only partly explained by joint pathophysiology, varies significantly between individuals and may be partly driven by changes in periarticular tissues.
Alisa J. Johnson   +2 more
wiley   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

open access: yesArthritis &Rheumatology, Volume 78, Issue 8, Page 1674-1686, August 2026.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie   +12 more
wiley   +1 more source

Fibromyalgia and Risk of Alzheimer's DiseaseRelated Dementia: A Nationwide Bidirectional Case-Control Study. [PDF]

open access: yesGeriatrics (Basel)
Magen E   +6 more
europepmc   +1 more source

Perceptions of Fibromyalgia Across Career Stages: Survey Results From Internal Medicine Physicians and Medical Students

open access: yes
Musculoskeletal Care, Volume 24, Issue 3, September 2026.
Isabel Carulli   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy